Navigation Links
Bayer CropScience Purchases Land Adjacent to its Research Triangle Park Headquarters
Date:12/21/2012

RESEARCH TRIANGLE PARK, N.C. (PRWEB) December 20, 2012

Bayer CropScience LP today announced it has purchased nearly 70 acres of land located directly north of its current Research Triangle Park property at the intersection of T.W. Alexander Drive and North Carolina Highway 147 from the Research Triangle Foundation. This additional section of land provides the leading crop protection company the ability to expand its North American headquarters in the future.

“Bayer CropScience is committed to Research Triangle Park as its North American headquarters,” said Jim Blome, president and CEO of Bayer CropScience LP. “With this newly acquired property, we now have flexibility to expand our business and continue to develop innovative agricultural technologies to feed a hungry planet.”

In July, Bayer CropScience completed construction on a USD 20 million, 60,000 square-foot greenhouse, which is used for soy, corn and other broadacre crop research. In addition, the company recently announced plans to break ground in February on its North American Bee Care Center, a more than 6,600 square feet building in Research Triangle Park, which will serve as a gathering place for researchers, bee experts, students and other visitors to meet regularly with leading Bayer scientists.

The Research Triangle Foundation continues to see Bayer CropScience as an integral player in the growth and reputation of Research Triangle Park.

“Over the years, Bayer CropScience has played an important role in the Research Triangle Park’s research and development community,” said Bob Geolas, CEO of The Research Triangle Park. “The Foundation is happy to support Bayer as it continues to grow its presence and invest in the Park and what it stands for—innovation and economic growth. Biotech remains a focus for many of our companies here in RTP – and leaders like Bayer uphold our reputation as a R&D destination.”

###

About Bayer CropScience
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer CropScience, the subgroup of Bayer AG responsible for the agricultural business, has annual sales of EUR 7.255 billion (2011) and is one of the world’s leading innovative crop science companies in the areas of seeds, crop protection and non-agricultural pest control. The company offers an outstanding range of products including high value seeds, innovative crop protection solutions based on chemical and biological modes of action as well as an extensive service backup for modern, sustainable agriculture. In the area of non-agricultural applications, Bayer CropScience has a broad portfolio of products and services to control pests from home and garden to forestry applications. The company has a global workforce of 21,000 and is represented in more than 120 countries. This and further news is available at: press.bayercropscience.com.

Contact:
Bayer CropScience Media Hotline, 1-877-879-6162, or

Becca Hogan
External Communications Manager
Bayer CropScience
Tel: (919) 549-2998
Email: becca(dot)hogan(at)bayer(dot)com

USA-BCS-2012-0523

Find more information at http://www.bayercropscience.us.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at http://www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Read the full story at http://www.prweb.com/releases/2012/12/prweb10258788.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Bayer CropScience Announces Registration for use of Alion on Grapes in California
2. Bayer CropScience Hosts Inaugural Vegetable Future Forum in Monheim
3. Bayer CropScience Launches Third Annual Young Farmer Sustainability Award Program
4. Bayer CropScience Provides a Glimpse of SeedGrowth™ Innovation
5. Growers Choose the Bayer CropScience LibertyLinkSystem for Yield and Performance
6. Bayer Bee Care Center Helps Solve Bee Health’s Toughest Challenges
7. Bayer CropScience Announces LibertyLink LinkUp Offer Increased for 2013 Season
8. QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
9. Bayer Advanced(TM) Sets Sights on New Partnerships in 2013
10. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
11. Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... and NEW YORK , Feb. 16, ... completion of their $7M Series B financing, adding an ... the $3.5M led by Mesa Verde Venture Partners and ... resources will be directed towards further accelerating commercial adoption ... comprehensive genomic profiling test and expanding the Paradigm cancer ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... -- Windtree Therapeutics, Inc. (Nasdaq: WINT ), ... therapies for respiratory diseases, will host a conference call ... EST on Thursday, February 16, 2017 to provide updates ... announced closing of a $10.5 million private offering and ... in the live call and take part in the ...
Breaking Biology Technology:
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to its ... meaningful advances worldwide, The Japan Prize Foundation today ... who have pushed the envelope in their respective ... Communication. Three scientists are being recognized with the ... that not only contribute to the advancement of ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
Breaking Biology News(10 mins):